Acadia Healthcare (NASDAQ:ACHC – Free Report) had its price objective boosted by TD Cowen from $22.00 to $24.00 in a research report report published on Thursday morning,Benzinga reports. TD Cowen currently has a buy rating on the stock.
A number of other analysts have also weighed in on the company. Guggenheim lowered their target price on Acadia Healthcare from $27.00 to $22.00 and set a “buy” rating for the company in a report on Monday. Cantor Fitzgerald set a $17.00 price objective on Acadia Healthcare in a research note on Wednesday, December 3rd. Jefferies Financial Group lowered Acadia Healthcare to a “hold” rating in a research note on Thursday, January 22nd. Leerink Partners boosted their target price on shares of Acadia Healthcare from $14.00 to $22.00 and gave the stock a “market perform” rating in a report on Thursday. Finally, UBS Group lowered their price target on shares of Acadia Healthcare from $28.00 to $24.00 and set a “buy” rating on the stock in a report on Wednesday, December 3rd. Seven analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $20.69.
Get Our Latest Stock Analysis on Acadia Healthcare
Acadia Healthcare Trading Up 7.0%
Acadia Healthcare (NASDAQ:ACHC – Get Free Report) last issued its earnings results on Wednesday, February 25th. The company reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of $0.03 by $0.04. Acadia Healthcare had a negative net margin of 33.29% and a positive return on equity of 6.53%. The business had revenue of $821.46 million for the quarter, compared to the consensus estimate of $800.10 million. During the same period in the prior year, the firm earned $0.64 EPS. The company’s revenue for the quarter was up 6.1% compared to the same quarter last year. Acadia Healthcare has set its FY 2026 guidance at 1.300-1.550 EPS and its Q1 2026 guidance at 0.250-0.300 EPS. On average, research analysts anticipate that Acadia Healthcare will post 3.38 EPS for the current year.
Hedge Funds Weigh In On Acadia Healthcare
Hedge funds have recently modified their holdings of the stock. EverSource Wealth Advisors LLC raised its position in shares of Acadia Healthcare by 54.8% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,404 shares of the company’s stock valued at $32,000 after purchasing an additional 497 shares during the last quarter. Federated Hermes Inc. raised its holdings in shares of Acadia Healthcare by 1.5% in the fourth quarter. Federated Hermes Inc. now owns 43,913 shares of the company’s stock worth $623,000 after buying an additional 668 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in shares of Acadia Healthcare by 0.9% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 74,907 shares of the company’s stock worth $1,063,000 after buying an additional 696 shares during the period. Public Employees Retirement System of Ohio grew its holdings in shares of Acadia Healthcare by 2.8% during the third quarter. Public Employees Retirement System of Ohio now owns 31,335 shares of the company’s stock valued at $776,000 after buying an additional 867 shares during the last quarter. Finally, Treasurer of the State of North Carolina grew its holdings in shares of Acadia Healthcare by 2.1% during the second quarter. Treasurer of the State of North Carolina now owns 42,502 shares of the company’s stock valued at $964,000 after buying an additional 867 shares during the last quarter.
Key Headlines Impacting Acadia Healthcare
Here are the key news stories impacting Acadia Healthcare this week:
- Positive Sentiment: Q4 revenue topped estimates — revenue of ~$821.5M (≈6% YoY growth) and rising admissions/patient days, which investors interpreted as signs of operational recovery. Acadia Healthcare’s (NASDAQ:ACHC) Q4 CY2025 Sales Top Estimates, Stock Jumps 10.8%
- Positive Sentiment: Company issued upbeat Q1 2026 guidance (EPS $0.25–$0.30 vs. consensus $0.11 and revenue $820–$830M vs. consensus ~$799.5M), suggesting sequential improvement into the year — a near‑term catalyst for the rally. Acadia Healthcare Announces Fourth Quarter and 2025 Results
- Positive Sentiment: Multiple analysts raised targets and reiterated buys/outperform (RBC to $28, UBS to $27, TD Cowen to $24), providing fresh broker support and likely amplifying the rally. Benzinga — analyst target/ratings summaries
- Neutral Sentiment: Opinion pieces and analyst notes highlight a returning CEO and new management strategy that could improve execution; these are longer‑term positives but don’t guarantee immediate financial turnaround. Acadia Healthcare: New Management Deserves A Shot At Turning Business Around
- Negative Sentiment: FY‑2026 EPS guidance was lowered relative to sell‑side consensus (guidance $1.30–$1.55 vs. consensus ~$1.75), which caps upside and raises questions about full‑year margins and profitability. Acadia Healthcare Announces Fourth Quarter and 2025 Results
- Negative Sentiment: EPS collapsed year‑over‑year (reported $0.07 vs $0.64 prior year) and operating profit fell sharply — a reminder that revenue strength hasn’t yet translated into sustained earnings recovery. Acadia Healthcare Q4 Earnings Beat Estimates on Rising Admissions
- Negative Sentiment: Large short interest reported earlier in February (≈32.45M shares, ~35.9% sold short; ~7.3 days to cover) increases volatility risk — it can both pressure the stock and set up rapid squeezes. (Data reported in short‑interest updates.)
About Acadia Healthcare
Acadia Healthcare Company, Inc (NASDAQ: ACHC) is a publicly traded provider of behavioral healthcare services headquartered in Franklin, Tennessee. Founded in 2005, the company has grown through organic expansion and strategic acquisitions to establish itself as a leading specialist in mental health and addiction treatment across the United States.
Acadia operates a diversified network of inpatient psychiatric hospitals, residential treatment centers, outpatient clinics and intensive outpatient programs.
Further Reading
- Five stocks we like better than Acadia Healthcare
- The gold chart Wall Street is terrified of…
- America’s 1776 happening again
- This makes me furious
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
Receive News & Ratings for Acadia Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acadia Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
